CED Archives

Patient, Consumer, and Public Health Coalition Letter to Congress on CMS Limited Coverage for Newly Approved Alzheimer’s Drugs

February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.

Comment Regarding AHRQ’s Analysis of Requirements for Coverage with Evidence Development (CED) – Topic Refinement

September 28, 2022: NCHR support AHRQ’s overall report and recommendations for the Centers for Medicare and Medicaid Services (CMS) to update their CED requirements.